XML 50 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Sep. 27, 2025
Accounting Policies [Abstract]  
Supplemental Cash Flow Statement Information
Supplemental Cash Flow Statement Information
 Years Ended
September 27, 2025September 28, 2024September 30, 2023
Cash paid during the period for income taxes$224.3 $137.9 $296.1 
Cash paid during the period for interest$112.9 $117.1 $105.4 
Non-Cash Financing Activities:
Fair value of contingent consideration at acquisition$— $— $1.1 
Cash paid for income taxes presented above is net of tax refunds of $7.0 million, $19.6 million and $39.3 million for fiscal years 2025, 2024 and 2023, respectively. The fiscal 2025, 2024 and 2023 refunds received primarily related to tax filings and over-payments made in the ordinary course of business.
Schedule of Inventories
Inventories consisted of the following:
September 27, 2025September 28, 2024
Raw materials$247.8 $251.4 
Work-in-process68.4 62.0 
Finished goods363.2 366.4 
$679.4 $679.8 
Schedule of Property, Plant and Equipment
Property, plant and equipment consisted of the following:
Estimated Useful LifeSeptember 27, 2025September 28, 2024
Equipment
3–10 years

$383.8 $378.1 
Equipment under customer usage agreements
3–8 years

586.8 523.1 
Buildings and improvements
20–35 years

256.1 247.1 
Leasehold improvementsShorter of the Original Lease Term
or Estimated Useful Life
49.1 44.0 
Land40.9 40.8 
Furniture and fixtures
5–7 years

26.5 24.6 
Finance lease right-of-use asset9.2 8.8 
1,352.4 1,266.5 
Less - accumulated depreciation and amortization(792.8)(728.7)
$559.6 $537.8 
Schedule of Intangible Assets
Intangible assets consisted of the following:
 
  September 27, 2025September 28, 2024
DescriptionGross
Carrying
Value
Accumulated
Amortization
Gross
Carrying
Value
Accumulated
Amortization
Acquired intangible assets:
Developed technology$4,540.2 $4,015.8 $4,567.0 $3,834.0 
In-process research and development3.1 — 25.1 — 
Customer relationships593.7 578.1 609.7 569.8 
Trade names262.8 229.2 260.3 224.5 
Total acquired intangible assets$5,399.8 $4,823.1 $5,462.1 $4,628.3 
Internal-use software20.6 15.4 25.7 20.5 
Capitalized software embedded in products33.5 26.3 30.2 24.6 
Total intangible assets$5,453.9 $4,864.8 $5,518.0 $4,673.4 
Schedule of Estimated Amortization Expense
The estimated amortization expense at September 27, 2025 for each of the five succeeding fiscal years was as follows:
 
Fiscal 2026$149.9 
Fiscal 2027$62.8 
Fiscal 2028$59.5 
Fiscal 2029$53.3 
Fiscal 2030$51.0 
Rollforward of Goodwill Activity by Reportable Segment
A rollforward of goodwill activity by reportable segment from September 28, 2024 to September 27, 2025 is as follows: 
DiagnosticsBreast HealthGYN SurgicalSkeletal HealthTotal
Balance at September 28, 2024$1,365.8 $934.6 $1,134.7 $8.0 $3,443.1 
Gynesonics acquisition
— — 191.0 — 191.0 
Foreign currency and other adjustments2.9 3.8 (0.2)— 6.5 
Balance at September 27, 2025$1,368.7 $938.4 $1,325.5 $8.0 $3,640.6 
Schedule of Other Assets
Other assets consisted of the following:
September 27, 2025September 28, 2024
Other Assets
Tax receivable$37.4 $37.5 
Operating lease right of use assets94.1 92.2 
Life insurance contracts78.6 71.0 
Deferred tax assets239.8 128.8 
Strategic investments78.5 54.3 
Other29.1 27.0 
$557.5 $410.8 
Schedule of Accumulated Other Comprehensive Income (Loss) Related to Derivatives
Realized and unrealized gains and losses from these contracts, which were the only derivative contracts not designated for hedge accounting, for the years ended September 27, 2025, September 28, 2024, and September 30, 2023 were as follows:
Years Ended
September 27, 2025
September 28, 2024
September 30, 2023
Amount of realized gain (loss) recognized in income
Forward foreign currency contracts$2.5 $3.9 $1.3 
Foreign currency option contracts— — (4.0)
$2.5 $3.9 $(2.7)
Amount of unrealized gain (loss) recognized in income
Forward foreign currency contracts$8.1 $(20.9)$(7.5)
Foreign currency option contracts(0.8)0.8 (5.5)
$7.3 $(20.1)$(13.0)
Amount of gain (loss) recognized in income
Total$9.8 $(16.2)$(15.7)
Schedule of Derivative Instruments on the Consolidated Balance Sheets
The table below presents the fair value of the Company’s derivative financial instruments as well as their classification on the balance sheet as of September 27, 2025:
Balance Sheet LocationSeptember 27, 2025September 28, 2024
Assets:
Derivative instrument designated as a cash flow hedge:
Interest rate swap contractsPrepaid expenses and other current assets$3.2 $3.1 
$3.2 $3.1 
Derivatives not designated as hedging instruments:
Forward foreign currency contractsPrepaid expenses and other current assets$1.6 $— 
Foreign currency option contractsPrepaid expenses and other current assets— 0.8 
$1.6 $0.8 
Liabilities:
Derivative instruments designated as a cash flow hedge:
Interest rate swap contractsOther long-term liabilities$— $0.2 
Total$— $0.2 
Derivatives not designated as hedging instruments:
Forward foreign currency contractsAccrued expenses$6.1 $12.6 
Schedule of Unrealized Loss Recognized in AOCI
The following table presents the unrealized gain (loss) recognized in AOCI related to interest rate swaps for the following reporting periods:
Years Ended
September 27, 2025
September 28, 2024
September 30, 2023
Amount of loss recognized in other comprehensive income (loss), net of taxes:
Interest rate swap$(0.1)$(18.3)$(9.2)
Total$(0.1)$(18.3)$(9.2)
Accounts Receivable Reserve Activity
The following is a rollforward of the allowance for credit losses for fiscal 2025, 2024 and 2023:
 
Balance at
Beginning
of Period
Charged to
Costs and
Expenses
Write-
offs and
Payments
Balance at
End of
Period
Period Ended:
September 27, 2025$41.4 $0.3 $(3.5)$38.2 
September 28, 2024$38.5 $5.7 $(2.8)$41.4 
September 30, 2023$37.7 $3.7 $(2.9)$38.5 
Schedule of Reconciliation of Basic and Diluted Share Amounts
A reconciliation of basic and diluted share amounts for fiscal 2025, 2024, and 2023 was as follows:
September 27, 2025September 28, 2024September 30, 2023
Basic weighted average common shares outstanding226,156 235,723 246,772 
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock units1,417 1,830 2,059 
Diluted weighted average common shares outstanding227,573 237,553 248,831 
Weighted-average anti-dilutive shares related to:
Outstanding stock options and restricted stock units2,150 1,171 981